

Routine annual influenza vaccination is recommended for all people aged 6 months and older who do not have a contraindication. **The Vermont Immunization Program will provide influenza vaccine for all patients age 6 months through 18 years.** All vaccines supplied will be quadrivalent preservative-free formulations in prefilled syringes.

- The 2017-18 quadrivalent influenza vaccines used in the United States contain an A/Michigan/45/2015 (H1N1)pdm09-like virus, an A/Hong Kong/4801/2014 (H3N2)-like virus, , a B/Brisbane/60/2008-like (B/Victoria lineage) virus, and a B/Phuket/3073/2013-like (B/Yamagata lineage) virus. This represents a change in the influenza A (H1N1) pdm09 virus component compared with the composition of the 2016–17 influenza vaccine.
- The Advisory Committee on Immunization Practices (ACIP) voted not to recommend use of live attenuated influenza vaccine (LAIV) during the 2017–18 season due to concerns about its effectiveness against (H1N1)pdm09 viruses during the 2013–14 and 2015–16 seasons.
- The [“2017-2018 Prevention and Control of Seasonal Influenza with Vaccines, Recommendations of the ACIP”](#) was published in the Morbidity and Mortality Weekly Report (MMWR) on 8/25/2017.
- **New this season, State-supplied vaccine for pediatric use will include FluLaval, manufactured by ID Biomedical (distributed by GlaxoSmithKline) and licensed for use in individuals 6 months and older. Children age 6 through 35 months receive the same 0.5 ml dose as is used in older children and adults. The dose administered to all ages is 0.5ml.**
 - FluLaval will primarily be supplied to Family Practices for patients 6 months – 18 years old.
 - Pediatric practices will primarily receive the two Sanofi Fluzone vaccines, 0.25ml presentation for patients 6 – 35 months, and 0.5ml presentation for 3 – 18-year-old patients.

Influenza vaccines for pediatric use supplied by the VT Department of Health 2017-18				
Vaccine NDC Manufacturer	Package Dose	Age	Preservative Free	Type
Fluzone® Quadrivalent 49281-0417-50 Sanofi	Single dose 0.5ml syringe	3 - 18 years	Yes	Inactive IIV4
Fluzone® Quadrivalent 49281-0517-25 Sanofi	Single dose 0.25ml syringe	6–35 months	Yes	Inactive IIV4
FluLaval® Quadrivalent 19515-0912-52 ID Biomedical	Single dose 0.5ml syringe	6 months - 18 years	Yes	Inactive IIV4

Flu Vaccine Administration Information

What is the appropriate dosing and schedule for young children?


The following children will need 2 doses of influenza vaccine in the 2017-18 season, administered at least 4 weeks apart.

- ☐ Children aged 6 months through 8 years who have never been vaccinated against influenza or for whom vaccination history is unknown.
- ☐ Children aged 6 months through 8 years who have not received at least 2 doses of seasonal influenza vaccine (trivalent or quadrivalent) before July 1, 2017.

The following children will require only 1 dose of influenza vaccine for 2017–18:

- ☐ Children 6 months through 8 years who have received at least 2 doses of seasonal influenza vaccine (trivalent or quadrivalent) before July 1, 2017.
- ☐ Children 9 years of age and older.

Influenza vaccine dosing algorithm for children aged 6 months through 8 years — Advisory Committee on Immunization Practices, United States, 2017–18 influenza season



Injectable Influenza Vaccine Dosing

Age	Dose	Number of doses
6 - 35 months	0.25 mL (Fluzone) 0.5 mL (FluLaval)	1 or 2
3 - 8 years	0.5 mL	1 or 2
9 years to adult	0.5 mL	1

Concurrent Administration of Influenza Vaccine with Other Vaccines

Inactivated influenza vaccines do not interfere with the immune response to other inactivated vaccine or to live vaccines.

Vaccine Information Statement (VIS)

The [Influenza VIS](#) can be found on the CDC website. The page includes links to VIS translations in many languages. Please note: The Flu VIS is no longer updated every year. The edition dated 8/7/2015 should be used for the current flu season.

Entering Influenza Immunizations into the IMR – 2017-18

Flu shots – they are not all the same! The guidance below can help you record influenza immunizations accurately in your Electronic Health Record or in the Vermont Immunization Registry. It includes all influenza formulations licensed in the US during this influenza season.

Trade Name	MFR	Licensed age	Trivalent or Quadrivalent	Other	Best IMR Selection	State Supplied?*	CVX code**
Afluria®	Sequirus	≥ 9 years	Tri (IIV3)		Influenza IIV3 preservative free		140
Afluria®	Sequirus	≥ 9 years	Tri (IIV3)		Influenza IIV3		141
Afluria®	Sequirus	≥ 18 years	Quad (IIV4)		Influenza IIV4 preservative free		150
Afluria®	Sequirus	≥ 18 years	Quad (IIV4)		Influenza IIV4		158
Fluad®	Sequirus	≥ 65 years	Tri (IIV3)	Adjuvanted	influenza, trivalent, adjuvanted****		168
Fluarix®	Glaxo Smith Kline	≥ 3 years	Quad (IIV4)		Influenza IIV4 preservative free		150
FluBlok®	Protein Science	≥ 18 years	Tri (IIV3)	Cell culture derived, RIV3	Influenza Recombinant preservative free		155
Flucelvax®	Sequirus	≥ 4 years	Quad (IIV4)	Cell culture derived	Influenza, injectable, MDCK, preservative free, quadrivalent		171
Flulaval®	ID Biomedical	≥ 6 months	Quad (IIV4)		Influenza IIV4		158
Flulaval®	ID Biomedical	≥ 6 months	Quad (IIV4)		Influenza IIV4 preservative free	x	150
Flumist®	MedImmune	2-49 years	Quad (IIV4)	Nasal	Influenza LAIV4 Intranasal***		149
Fluvirin®	Sequirus	≥ 4 years	Tri (IIV3)		Influenza IIV3		141
Fluvirin®	Sequirus	≥ 4 years	Tri (IIV3)		Influenza IIV3 preservative free		140
Fluzone®	Sanofi Pasteur	≥ 3 years	Quad (IIV4)		Influenza IIV4 preservative free	x	150
Fluzone®	Sanofi Pasteur	≥ 6 months	Quad (IIV4)		Influenza IIV4		158
Fluzone®	Sanofi Pasteur	6-35 months	Quad (IIV4)	Pediatric 0.25 dose	Influenza IIV4 Pediatric preservative free	x	161
Fluzone®	Sanofi Pasteur	18-64 years	Quad (IIV4)	intradermal	influenza, intradermal, quadrivalent, preservative free		166
Fluzone®	Sanofi Pasteur	≥ 65 years	Tri (IIV3)	High Dose	Influenza High Dose IIV3****		135
[historical]	n/a	n/a	n/a		Influenza, Unspecified		88
[historical]	n/a	n/a	n/a	Nasal	Influenza, Nasal		111
[historical]	n/a	n/a	n/a	Nasal	Influenza, Nasal Unspecified		151

*State supplied for pediatric use by participants in Vaccines for Children Program.

**Code needed for HL7 messaging. You may need to add this to your electronic health record.


*** Not recommended for use in 2017-18 season by Advisory Committee on Immunization Practices.

****Licensed for use in age 65+ years only


Between 2004 and 2012, 830 pediatric deaths were attributed to influenza in the US. Vaccination remains the most effective means to prevent infection, and the Vermont Immunization Registry is an excellent resource for assessing how well this vulnerable population is protected. By the age of 2, children should have received at least two doses of the flu vaccine. The map below shows the coverage rates for last year's flu season by county, showing the percentage of 2-year-olds that received two doses by age 2. The overall state rate is 62%.

Seasonal vaccination against the flu remains important throughout a person's life. The Vermont Immunization Registry is a terrific resource for assessing this larger population as well, especially since the Registry is now getting data from all hospital clinics, and most Vermont pharmacies, where many older Vermonters get their annual flu shot.

The graph below demonstrates that last year flu vaccination rates were low in the adolescent and young adult population, and higher in young children and older adults.



Data source: Vermont Immunization Registry



Data source: Vermont Immunization Registry, US Census denominator

Rollout of the new Vaccine Inventory Management System (VIMS) has begun! Over the next few months, the Immunization Program staff will enroll, train and transition all VFC/VFA providers to VIMS. This system will replace VTrckS for vaccine ordering and all related reporting. All VFC/VFA providers will be required to use VIMS to order state-supplied vaccine. The implementation of VIMS represents a major change that will provide better vaccine management and improve vaccine ordering operations throughout the state.

What can I do now?

Ensure you can log on to the Vermont Immunization Registry (IMR). VIMS is accessed through the IMR, so you'll only have to manage one password for both the IMR and VIMS. If you do not already have access to the IMR, visit the [IMR website](#) and complete a Confidentiality Agreement or call (888) 688-4667.

What can I expect?

You will be contacted to schedule a 45-minute phone training with Immunization Program staff. During this interactive session, you will reconcile your inventory, enter any returns, wastage or transfers and place your first order. You will also be introduced to the reporting features in VIMS.

The Immunization Program will upload your VTrckS Inventory on Hand into VIMS for you. We will email you a copy of the inventory one week prior to your transition. It is important that you use the emailed data to take an inventory count so that you will have real data when entering your first order and supporting documents. Plan on taking an inventory count a day or two before your scheduled one-on-one training.

We recommend that you review the training materials ahead of your scheduled training, which will be posted to the [Vaccine Ordering](#) page of the Health Department website as they become available.

What if I need to place a vaccine order before my scheduled training?

Continue to order vaccine based on your assigned order schedule. We've scheduled the timing of your training and transition to coincide with your assigned order schedule. Please email the Immunization Program at AHS.VDHIimmunizationProgram@vermont.gov if you need to place a vaccine order outside of your scheduled order period.

Do I still need to fax paper temperature logs with my order?

No. Beginning August 1st, VFC/VFA practices are no longer required to fax paper temperature logs with vaccine orders; rather, monthly submission of data logger downloads is required. An email, dated 7/20/17, was sent to all vaccine contacts informing them of this change.

Will I still need to access VTrckS?

You should continue to use VTrckS until you receive training on VIMS. After VIMS training your access to VTrckS will be removed.

Sanofi Pasteur has announced the total depletion of their supply of YF-Vax. For a limited time, some Vermont or surrounding states' travel clinics may still have this vaccine in stock. Travel vaccine clinic contact information can be found on [the CDC webpage](#) or the VT Health Department [Vermont Travel Clinics webpage](#)

Sanofi Pasteur has worked with the FDA to make an alternative yellow fever vaccine, Stamaril, available only at select locations due to limited supply. Stamaril is available in and around Vermont at

The University of Vermont Medical Center Inc.
111 Colchester Avenue
Burlington, VT 05401
Phone: 802-847-2821

Dartmouth-Hitchcock Medical Center Infectious Disease and International Health Clinic
One Medical Center Drive
Lebanon, NH 03756
Phone: 603-650-6060

Passport Health of New York State
125 Wolf Rd., Ste. 106
Albany, NY 12205
Phone: 855-729-2479